Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03336333 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene.
- Active
- Registry status
- Phase 3
- Development phase
- 590
- Enrollment target
- 20
- Study locations
NCT03336333 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 590 participants, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT03336333, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 590 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Venetoclax
- DRUG Rituximab
- DRUG Bendamustine
Study Locations (20)
New York
- Icahn School of Medicine At Mount Sinai - New York
- Columbia University Medical Center - New York
- University of Rochester - Rochester
Missouri
- Research Medical Center - Kansas City
- Washington University - St Louis
Washington
- Va Puget Sound Health Care System - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
New South Wales
- Concord Repatriation General Hospital - Concord
- The Tweed Valley Hospital - Cudgen
Georgia
- Augusta University - Augusta
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03336333
The ClinicalTrials.gov registry entry for NCT03336333 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 179-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (230% higher). The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Zanubrutinib is the first listed.
NCT03336333 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Missouri, Washington.
Frequently Asked Questions
What is clinical trial NCT03336333 about?
NCT03336333 is a clinical study titled "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL". To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
What is the current status of trial NCT03336333?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 590 participants. The study started on 2017-10-31. Estimated completion is 2027-10-31.
What conditions does trial NCT03336333 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT03336333?
The interventions under investigation include: Zanubrutinib (DRUG), Venetoclax (DRUG), Rituximab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT03336333?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03336333 being conducted?
This trial has 20 study locations across Georgia, Illinois, Massachusetts, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 3
-
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 3
-
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RECRUITING · Phase 3
-
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RECRUITING · Phase 3
-
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.